-
Benchmark Reiterates Speculative Buy Rating on CapsoVision Inc (CV)
-
CapsoVision (CV) Reports Q3 Loss of $0.17
-
CapsoVision seeks FDA breakthrough status for pancreatic cancer capsule
-
CapsoVision (CV) Misses Q2 EPS by 202c
-
Benchmark Starts CapsoVision Inc (CV) at Speculative Buy
-
Roth/MKM Starts CapsoVision Inc (CV) at Buy
-
Recent IPO CapsoVision (CV) Surges 140%
-
Capsovision (CV) Opens At $5, IPO Priced At $5
-
CapsoVision (CV) Prices 5.5M Share IPO at $5/sh
-
CapsoVision (CV) Files for 5.25M Share IPO at $5-$5.50/sh
-
CapsoVision (CV) Files for Proposed IPO

